Scaffold Hopping & Navigation in Drug Discovery

• Scaffold hopping and navigation is a method for redesigning a molecule’s core structure to generate new chemotypes while retaining essential pharmacophoric interactions.
• It employs strategies ranging from knowledge-guided docking to diffusion and consistency models, enabling efficient exploration of bioactive chemical space and optimized drug profiles.
• The approach supports rapid lead optimization and IP navigation by focusing on metrics such as connectivity, diversity, and novelty, validated through benchmarks like QED and docking scores.

Scaffold hopping is a central strategy in contemporary drug discovery, defined by the systematic modification or replacement of a molecule’s core structure—the “scaffold”—while preserving the functional groups responsible for target binding. This technique enables the exploration of vast chemical space, navigation of intellectual property landscapes, and optimization of pharmacological profiles. Recent advances in structure-based drug design (SBDD), machine learning, and generative modeling have significantly expanded the capabilities for scaffold hopping and navigation, allowing precise, pocket-conditioned, and efficient exploration of bioactive chemical space.

1. Fundamental Principles of Scaffold Hopping

Scaffold hopping is the process of redesigning the core (scaffold) of a bioactive molecule to generate new chemotypes that maintain pharmacological activity. Typically, the scaffold is defined by Bemis–Murcko extraction, with the remaining moieties classified as “functional groups” that anchor critical interactions with the target. Motivations for scaffold hopping include:

• Preservation of key pharmacophores and protein-ligand interactions.
• Introduction of novel ring systems or linkers to optimize potency, selectivity, or ADMET properties.
• Navigation around intellectual property constraints.
• Mitigation of adverse liabilities in the original scaffold (e.g., toxicity, metabolic instability).

Scaffold hopping narrows the vast drug-like chemical space (on the order of $10^{63}$ molecules for under 500 Da (Yoo et al., 2024)) by focusing on bioisosteric and pharmacophore-conserved cores, thus supporting efficient structure-activity relationship (SAR) development and hit-to-lead optimization.

2. Classical and Knowledge-Guided Scaffold Docking

Template-based methods utilize prior structural knowledge by transferring binding poses from a known protein-ligand complex to related scaffolds. SkeleDock embodies this knowledge-guided approach (Varela-Rial et al., 2020):

• Input: Receptor and template ligand structures (PDB), and a set of query ligands.
• Graph Matching: Constructs molecular graphs for both template and query; identifies a maximum common subgraph (MCS) mapping atoms across scaffolds.
• Tethering and Dihedral Autocompletion: Mapped atoms are harmonically biased toward the template coordinates; unmapped dihedral atoms can be recursively matched via “dihedral autocompletion” to tolerate minor scaffold changes.
• Pose Refinement and Scoring: Employs rDock’s tethered docking, partially or fully constraining mapped atoms, while sampling non-mapped dihedrals. Scoring function incorporates van der Waals, Coulombic, hydrogen-bond, solvation, clash, and tethering terms.

Macrocycle scaffolds are handled robustly, with the 3D ring geometry carried over directly if all macrocyclic atoms are mapped. Evaluation on PDBbind fragmentations and D3R Grand Challenge macrocycles confirms significantly higher pose recovery than unconstrained or MCS-only docking, especially in fragment-guided regimes. SkeleDock enables systematic chemical space navigation through series of scaffold hops, facilitating rational library design (Varela-Rial et al., 2020).

3. Diffusion and Consistency Model Paradigms for Scaffold Hopping

Generative modeling frameworks now extend scaffold hopping to direct 3D structure-based synthesis, leveraging both ligand and protein pocket information.

3.1 Diffusion Models: DiffHopp

DiffHopp introduces an E(3)-equivariant graph denoising diffusion model conditioned on protein pocket and functional group context (Torge et al., 2023). The model:

• Learns $$p_\theta(\text{scaffold}|\text{pocket},\text{functional group})$$ via a denoising process over atom-type and coordinate graphs.
• At each diffusion timestep, predicts noise for both atomic features and coordinates using a stack of geometric vector perceptron (GVP)-based message passing layers.
• After iterative reverse diffusion (typically $T=500$ steps), assembles the newly generated scaffold with the fixed functional group, and performs structure relaxation.

DiffHopp achieves high validity (0.914 connectivity), chemical diversity (0.592), near-complete novelty (0.998), robust drug-likeness (QED 0.612), and docking scores competitive with test-set ligands. The model is explicitly pocket-conditioned, allowing target-specific navigation of scaffold space (Torge et al., 2023).

3.2 Consistency Models and Reinforcement Learning: TurboHopp

TurboHopp leverages consistency models for accelerated 3D scaffold hopping (Yoo et al., 2024). Key features:

• Utilizes a consistency function $f_\theta$ to map noisy graph states directly to denoised scaffolds, sampling in $N\ll T$ steps ($50$–$150$), achieving $\sim$5–30$\times$ inference acceleration over diffusion.
• Retains SE(3)-equivariant message-passing to ensure physically realistic atom and feature updates.
• Incorporates reinforcement learning for consistency models (RLCM) using PPO, optimizing for domain-specific objectives such as binding affinity, steric clash minimization, QED, and synthetic accessibility (SA).

TurboHopp demonstrates improved connectivity (e.g., 0.948 @ 100 steps), comparable or superior docking (QVina –8.272) and QED (0.589), and drastic reduction in wall-clock time (from 107.1 s for DiffHopp to 5.69 s for TurboHopp-100). RL-augmented models further enhance multi-objective navigation, e.g., TurboHoppRL-50 achieves elevated diversity (0.869) and docking (–9.804), demonstrating broad applicability (Yoo et al., 2024).

4. Scaffold Representation, Navigation, and Evaluation Metrics

All modern scaffold hopping frameworks utilize explicit scaffold extraction (typically Murcko–Bemis) and functional group decomposition, either via cheminformatics tools (e.g., RDKit) or by graph-based methods (Torge et al., 2023, Yoo et al., 2024). Chemical space navigation proceeds as follows:

• Systematically replace the scaffold while constraining functional groups and pocket complementarity.
• Sample novel scaffold geometries and atom-type assignments such that reconstructed ligands preserve target binding.
• Evaluate candidate molecules using connectivity, diversity (pairwise Tanimoto), novelty, QED, SA, and docking scores.

Below is a tabular summary of methodological performance (as reported for PDBBind benchmark):

Method	Connectivity	Diversity	Novelty	QED	Docking (QVina)	Steps	Inference Time (s)
DiffHopp (500)	0.918	0.589	0.999	0.621	–7.923	500	107.1
TurboHopp-50	0.872	0.562	1.000	0.576	–7.823	50	3.19
TurboHopp-100	0.948	0.563	0.997	0.589	–8.272	100	5.69

TurboHopp also outperforms targeted inpainting models in the CrossDocked dataset for validity, connectivity, QED, and efficiency.

5. Practical Implications and Applications in Drug Discovery

High-efficiency scaffold hopping models enable practical workflows in medicinal chemistry:

• Systematic docking and prioritization of library-scale scaffold variations using template-based or generative frameworks.
• Accelerated exploration of congeneric series by maintaining mapped pharmacophores while sampling new chemotypes.
• Rapid screening and optimization of IP-navigated leads, especially when time-to-result is critical (e.g., TurboHopp enabling RL-based refinement due to reduced inference cost).

SkeleDock’s knowledge-guided paradigm provides efficient pose transfer and robust macrocycle handling (Varela-Rial et al., 2020); DiffHopp and TurboHopp supply highly automated, pocket-centric de novo navigation for hit expansion and lead optimization, with demonstrated competitive or superior benchmark results (Torge et al., 2023, Yoo et al., 2024).

6. Limitations, Future Directions, and Open Questions

Current generation models exhibit several challenges and future potential:

• Some consistency models (e.g., TurboHopp) show diminished scaffold diversity, possibly remediable by noise schedule refinements or bond/no-bond explicit diffusion channels (Yoo et al., 2024).
• Lack of explicit hydrogen or polarizability modeling may constrain accuracy for certain targets and ligand classes.
• Fully atomistic pocket representations and reaction-based synthetic constraints are anticipated to further refine scaffold fitness and synthetic tractability (Torge et al., 2023).
• Reward function engineering (integration of interaction fingerprints, explicit energy terms) and active learning loops are prospective extensions for both model quality and multi-objective optimization capabilities.

This suggests that future scaffold hopping and navigation frameworks will likely combine accelerated inference paradigms, richer physical and chemical priors, and RL-based fine-tuning to maximize practical utility across structure-based drug discovery campaigns.